Biotech Values

[Mufaso]

LGND - For reference, another milestone payment that Ligand may be entitled to is:

Under a license agreement with Viking for VK2809, Ligand is entitled to receive a $10 million milestone upon initiation of a Phase 3 clinical trial, other potential milestone payments and royalties of 3.5% to 7.5% on future worldwide sales of VK2809 by Viking.

I doubt Viking will take VK2809 (the NASH drug) as a standalone compound to phase 3 on their own so LGND may have to wait on this if it happens at all.

Other Viking compounds that LGND licensed to Viking when they formed Viking in 2014 include VK5211 the SARM compound Viking declined to take to Phase 3 when they couldn't partner it and VK0214 which is the X-ALD compound in phase 1B.

In case anyone is curious, AFAIK, Ligand still holds approx. 3.6 million shares of VKTX or 3.3% of Viking. LGND however has no ownership of Vikings lead compound VK2735 for obesity and won't get any royalties/milestones on that compound.